证券代码：300434 证券简称：金石亚药 公告编号：2023-023 四川金石亚洲医药股份有限公司 第四届监事会第九次会议决议公告 二、监事会会议审议情况 经研究讨论，会议达成如下决议： 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 四川金石亚洲医药股份有限公司（以下简称"公司"）第四届监事会第九次 会议于 2023 年 8 月 27 日上午以通讯表决方式召开，会议通知已于 2023 年 8 月 24 日以电子邮件或网络方式发出。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席汪进先生主持。本次会议的召集、召开符合《公司法》 及《公司章程》的有关规定，会议表决合法有效。 经审核，监事会认为：公司董事会编制和审核公司《2023 年半年度报告全 文及摘要》的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者 重大遗漏。 《2023 年半年度报告》详见公司同日在巨潮资讯网发布的相关公告，《2023 年半年度报告摘要》详见公司同日在巨潮资讯 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,242,603,080.88, representing a 17.95% increase compared to ¥1,053,504,604.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥218,786,883.71, a significant increase of 229.10% from ¥66,480,785.93 in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,753,270.89, up 244.90% from ¥56,756,082.55 in 2021[27]. - The net cash flow from operating activities for 2022 was ¥323,041,794.10, an increase of 136.84% compared to ¥136,395,575.72 in 2021[27]. - The total assets at the end of 2022 were ¥3,059,913,477.69, a 10.54% increase from ¥2,768,127,717.25 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥2,274,229,801.83, reflecting a 9.14% increase from ¥2,083,751,254.61 at the end of 2021[27]. - The basic earnings per share for 2022 was ¥0.54, a 217.65% increase from ¥0.17 in 2021[27]. - The weighted average return on equity for 2022 was 10.06%, up from 3.24% in 2021, indicating improved profitability[27]. - The company reported a net profit of ¥66,575,529.07 in Q1 2022, with a total operating revenue of ¥314,985,330.83 for the same quarter[29]. - The company reported a total non-operating income of 23,033,612.82, a significant increase of 136.5% compared to 9,724,703.38 in 2021[33]. Product Portfolio and Market Position - The company reported a significant reliance on its main product, the Kuaike cold medicine series, which accounted for a high percentage of both revenue and gross profit during the reporting period[5]. - The company has established over 90 drug production approval numbers and 6 health food production approval numbers, indicating a strong product portfolio[5]. - The company's main products include OTC medications such as "Kuaike" and "Xiaokuaike," which have maintained a leading market position in the cold medicine sector for three consecutive years[42]. - The company is focusing on the development of integrated raw material drug formulations and calcium mineral series products as future growth areas[6]. - The company is actively involved in the research and development of new drugs, focusing on respiratory, digestive, orthopedic, and pediatric areas[43]. - The company has developed multiple patented technologies in the field of ginsenoside RH2 extraction and produces high-quality health foods under the JinXing brand[44]. - The "Kuaike" and "Kuaike Junior" OTC drug series have become well-known cold medicine brands in China, with significant brand recognition and competitive advantages[44]. - The company is expanding its health food product range and has established a B2C e-commerce platform, reducing channel costs and inventory pressure compared to traditional manufacturers[44]. - The company is actively developing the "Kuaike Bencao" series of traditional Chinese medicine pieces, leveraging its brand influence and geographical advantages[45]. Competition and Market Risks - The company faces risks from increasing competition in the cold medicine and health food markets, which may threaten its market share due to new entrants and expanded capacities from existing companies[4]. - The company acknowledges the potential impact of regulatory changes in the pharmaceutical sector, which could alter the competitive landscape and operational models[6]. - The company anticipates ongoing price reductions in the pharmaceutical industry due to government policies, which may negatively impact average profit margins[7]. Research and Development - The company is investing in projects such as the Jinxi raw material drug project and the subsidiary formulation workshop renovation project, which involve substantial capital expenditures[6]. - The company has initiated a high-investment strategy in R&D, establishing a collaborative platform for innovation in the pharmaceutical sector[54]. - The company aims to enrich its product pipeline with various health supplements and generic drugs, focusing on expanding sales channels[69]. - The company is advancing multiple generic drug projects, including the consistency evaluation of Domperidone tablets, which is expected to enhance product competitiveness[69]. - Research and development (R&D) expenditure for 2022 amounted to CNY 39,184,819.23, accounting for 3.15% of operating revenue, down from 3.55% in 2021[71]. Supply Chain and Production - The company has a stable supply chain with long-term partnerships with key suppliers, although it remains vulnerable to potential raw material shortages and price increases due to external factors[5]. - The company operates five production bases across China, with a total area of over 400 acres, ensuring stable and efficient production capacity for various pharmaceutical forms[52]. - The company is investing in high-end raw materials, particularly calcium carbonate, to strengthen its market position in the calcium supplement category[47]. - The company has completed the development of a vacuum glass continuous production line, which is expected to significantly enhance production capacity and efficiency[72]. Marketing and Sales Strategy - The marketing network includes 1,200 chain agreements and over 92,000 cooperative chain stores, covering more than 90% of cities and 70% of counties in China[54]. - The company has built a large marketing team of over 1,000 members, enhancing its sales capabilities across both offline and online channels[55]. - The company is expanding its market presence through online TOB, TOC, and OTO platforms, aiming to enhance sales channels[93]. - The company plans to promote the upgrade of existing products, targeting the market with the KuaiKe cold medicine series and children's precision medication products over the next 2-3 years[92]. Environmental Responsibility - The company has established a comprehensive environmental management system to monitor and report on emissions and discharges[172]. - The company has implemented various pollution discharge standards across its subsidiaries to comply with environmental regulations[159][160][161]. - The company has established wastewater treatment facilities with a design capacity of 50 tons/day at the Asian Pharmaceutical Yagu plant and 15 tons/day at the Jinpan plant, achieving a stable operation rate of over 98%[175]. - The company has signed disposal contracts with qualified units for hazardous solid waste management, ensuring compliance with regulations[178]. - The company is committed to adhering to national environmental standards and has taken measures to monitor and control emissions effectively[169]. Governance and Compliance - The company has established a governance structure that complies with regulatory requirements and enhances decision-making processes[101]. - The board of directors consists of 11 members, including 4 independent directors, ensuring compliance with legal and regulatory standards[103]. - The company maintains strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[106]. - The company has established a clear internal control system with defined roles and responsibilities to ensure effective decision-making and management[150]. - The company has implemented an internal control audit for subsidiaries, enhancing risk management and control understanding[150]. Strategic Initiatives - The company plans to continue expanding its product lines and enhance its market presence through strategic initiatives and potential acquisitions[27]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its market share in the pharmaceutical industry[115]. - The company plans to utilize capital to strengthen its product pipeline and acquire strategically valuable targets[95]. - The company is focusing on improving management efficiency and addressing operational bottlenecks encountered in 2023[92].

证券代码：300434 证券简称：金石亚药 四川金石亚洲医药股份有限公司 投资者关系活动记录表 编号：2023-003 □特定对象调研 □ 分析师会议 投资者关系活动 □ 媒体采访 √ 业绩说明会 类别 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 投资者网上提问 时间 2023 年 5 月 19 日 (周五) 下午 15:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络 远程的方式召开业绩说明会 1、董事长、总经理魏宝康 上市公司接待人 2、董事、副总经理、董事会秘书林强 员姓名 3、财务总监王庆国 4、独立董事汪立荔 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问董事长先生，贵公司管理层是否有信心使公司业绩在未来 年度保持持续增长，将采取何种措施确保公司保持持续健康发展？公 投资者关系活动 司目前及未来在经营过程中所面临的最大风险是什么？ 主要内容介绍 尊敬的投资者，您好！未来公司将通过以下安排继续推动公司发展： 1、提升优化丰富现有产品，利 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300434 证券简称：金石亚药 公告编号：2023-015 四川金石亚洲医药股份有限公司 关于召开 2022 年度网上业绩说明会的公告 四川金石亚洲医药股份有限公司（以下简称"公司"）将于 2023 年 5 月 19 日（星期五）15:00-17:00 在全景网举行 2022 年度网上业绩说明会。本次业绩说 明会将采用网络远程方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长、总经理魏宝康先生、董事、副总经 理、董事会秘书林强先生、财务总监王庆国先生、独立董事汪立荔女士。 特此公告。 四川金石亚洲医药股份有限公司 董 事 会 二〇二三年五月十六日 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 18 日（星期四）12:00 前访问 http://ir.p5w.net/zj/，或扫描下方二 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,242,603,080.88, representing a 17.95% increase compared to ¥1,053,504,604.27 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥218,786,883.71, a significant increase of 229.10% from ¥66,480,785.93 in 2021[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,753,270.89, up 244.90% from ¥56,756,082.55 in 2021[27]. - The net cash flow from operating activities for 2022 was ¥323,041,794.10, an increase of 136.84% compared to ¥136,395,575.72 in 2021[27]. - The total assets at the end of 2022 amounted to ¥3,059,913,477.69, reflecting a 10.54% increase from ¥2,768,127,717.25 at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were ¥2,274,229,801.83, a 9.14% increase from ¥2,083,751,254.61 at the end of 2021[27]. - The basic earnings per share for 2022 was ¥0.54, representing a 217.65% increase from ¥0.17 in 2021[27]. - The weighted average return on equity for 2022 was 10.06%, up from 3.24% in 2021, indicating improved profitability[27]. - The company reported a net profit of ¥111,778,590.21 in Q4 2022, contributing significantly to the annual performance[29]. - The company reported a net profit of approximately 66.48 million yuan for the 2021 fiscal year, with a negative retained earnings balance of approximately -197.58 million yuan[141]. - The company reported a net profit margin of 12% for 2022, reflecting effective cost management and operational efficiency improvements[172]. Product Portfolio and Market Position - The company reported a significant reliance on its main products, with the sales revenue from the "Kuaike" cold medicine series accounting for a high percentage of total revenue and gross profit[5]. - The company has over 90 drug production approval numbers and 6 health food production approval numbers, indicating a strong product portfolio[5]. - The company's flagship products, "Kuaike" and "Xiaokuaike," have maintained leading positions in the OTC cold medicine market for three consecutive years[42]. - The company has developed a product matrix for its "Kuaike" and "Xiaokuaike" brands, expanding from a single cold medicine to a diversified over-the-counter (OTC) drug brand with multiple varieties[44]. - The "Kuaike" series products, including "Kuaike" compound acetaminophen and "Xiaokuaike" pediatric acetaminophen, have become well-known brands in China, achieving significant market recognition and competitive advantages[44]. - The company is actively developing products in respiratory, digestive, orthopedic, and pediatric areas, enhancing its competitive edge in the pharmaceutical sector[43]. - The company is enhancing its prescription drug offerings, including innovative Western medicines such as "Kuaike Xilin" and "Amoxicillin Clavulanate Potassium Dispersible Tablets," to expand its sales scale[45]. - The company is investing in the development of high-end raw materials, particularly calcium carbonate, to strengthen its market position in the calcium supplement category[45]. - The company is actively expanding its health food product line and has established a B2C e-commerce platform, leveraging online channels to reduce distribution costs and inventory pressure compared to traditional health food manufacturers[44]. Competition and Market Risks - The company faces risks from increasing competition in the cold medicine and health food markets, which may threaten its market share[4]. - The company anticipates ongoing price reductions in the pharmaceutical industry, which may negatively impact average profit margins and overall performance[7]. - The company acknowledges the potential impact of national procurement policies on pricing and market dynamics, which could affect its competitive position[6]. - The demand for cold medications has surged due to recent health policies and increased self-medication practices among consumers[39]. Research and Development - The company has a focus on developing new products, particularly in the calcium and mineral series, as part of its future growth strategy[6]. - The company is advancing multiple R&D projects, including a generic drug consistency evaluation project aimed at enhancing product competitiveness[67]. - Research and development (R&D) investment amounted to CNY 39,184,819.23, accounting for 3.15% of operating revenue[69]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficacy and safety[117]. - The company is investing heavily in R&D, allocating 200 million yuan, which is 16.67% of its total revenue, to develop new technologies and products[167]. Strategic Initiatives and Investments - The company is investing in projects such as the Jinxi raw material drug project and the subsidiary formulation workshop renovation project, which involve substantial capital expenditure[6]. - The company has established long-term stable partnerships with major suppliers to ensure raw material supply, although it remains vulnerable to price fluctuations and supply shortages due to external factors[5]. - The company is committed to becoming a trusted provider in the pharmaceutical health sector, focusing on quality, technology, and brand excellence[42]. - The company aims to enhance the promotion of existing products, particularly the Kuaike cold medicine matrix and the Kuaike children's medication series, targeting to develop star products within 2-3 years[90]. - The company is focusing on strategic upgrades and resource integration to enhance management efficiency and address operational bottlenecks encountered in 2023[90]. - The company plans to invest in and acquire traditional Chinese medicine production enterprises to strengthen its product pipeline[90]. - The company is exploring potential mergers and acquisitions to further strengthen its market position, with a focus on companies that complement its existing product lines[173]. Corporate Governance and Compliance - The company has implemented strict internal control standards for product quality, exceeding national standards, to mitigate risks associated with product quality control[6]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, aligning with legal regulations[104]. - The company has a board of directors consisting of 11 members, including 4 independent directors, ensuring compliance with legal and regulatory standards[101]. - The company has established a governance structure that complies with regulatory requirements, ensuring effective decision-making processes[99]. - The company has committed to maintaining independence from its controlling shareholders, ensuring no interference in its operational decisions[168]. Social Responsibility and Community Engagement - The company donated a total of ¥2,154,000 worth of products, including cold medicine, to frontline logistics personnel and local charities during the reporting period[158]. - The company actively participates in public welfare activities, contributing to local community development and maintaining good relations with government entities[157]. - The company has not reported any incidents of environmental pollution or violations of environmental protection laws during the reporting period[158]. - The company maintains a commitment to employee rights and welfare, providing comprehensive benefits including various types of insurance and paid leave[157]. Future Outlook - Future guidance suggests a projected revenue growth rate of approximately 15% for the upcoming fiscal year[112]. - The company has provided a revenue guidance of 1.5 billion CNY for the upcoming fiscal year, projecting a growth rate of 25%[117]. - The company aims to launch three new products in 2023, which are anticipated to generate approximately 500 million yuan in sales[169]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[170]. - The company is focused on market expansion and potential mergers and acquisitions to enhance its competitive position[198].

Financial Performance - The company's revenue for Q1 2023 was CNY 419,787,729.70, representing a 33.27% increase compared to CNY 314,985,330.83 in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was CNY 143,460,482.45, a significant increase of 115.49% from CNY 66,575,529.07 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 139,339,589.63, up 120.19% from CNY 63,281,312.18 year-on-year[4]. - The basic earnings per share for Q1 2023 was CNY 0.3571, reflecting a 110.06% increase from CNY 0.17 in the same quarter last year[4]. - Total operating revenue for Q1 2023 reached CNY 419,787,729.70, a significant increase from CNY 314,985,330.83 in the same period last year, representing a growth of approximately 33.3%[15]. - The company reported an operating profit of CNY 184,249,348.46, compared to CNY 80,200,301.74 in the previous year, reflecting an increase of approximately 129.1%[15]. - The total comprehensive income for Q1 2023 was CNY 142.50 million, compared to CNY 65.60 million in Q1 2022, reflecting an increase of 117.5%[16]. Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 3,040,493,261.49, a slight decrease of 0.63% from CNY 3,059,913,477.69 at the end of the previous year[4]. - The total current assets at the end of the reporting period were CNY 1,245,227,814.53, a slight decrease from CNY 1,261,062,751.33 at the beginning of the year, down by approximately 1.3%[12]. - The total liabilities decreased to CNY 594,640,857.64 from CNY 756,559,066.03, a reduction of about 21.4%[13]. - The total equity attributable to shareholders increased to CNY 2,417,690,284.28 from CNY 2,274,229,801.83, reflecting a growth of approximately 6.3%[13]. - The cash and cash equivalents decreased to CNY 386,869,329.36 from CNY 440,308,115.39, a decline of about 12.1%[12]. - Inventory levels rose to CNY 216,145,442.93 from CNY 197,369,370.03, an increase of approximately 9.5%[12]. Cash Flow - The net cash flow from operating activities for Q1 2023 was negative CNY 57,691,400.00, a decline of 475.91% compared to a positive cash flow of CNY 15,346,997.87 in the same period last year[4]. - Cash inflows from operating activities totaled CNY 360.72 million, compared to CNY 264.45 million in Q1 2022, indicating a rise of 36.4%[19]. - The total cash outflow from investing activities was CNY 4.65 million, compared to CNY 45.71 million in Q1 2022, showing a decrease of 89.8%[19]. - The net cash flow from financing activities was CNY 7.37 million, with no cash inflow reported in Q1 2022[20]. Market and Operational Performance - The company experienced a significant increase in market demand for its main products, leading to improved operational performance[7]. - The company has implemented production mechanism adjustments and optimized production processes to significantly increase output in response to market demand[7]. - Research and development expenses increased to CNY 17,587,226.51 from CNY 12,937,760.46, marking a rise of about 36.3%[15]. Foreign Exchange and Non-Recurring Items - The company reported non-recurring gains totaling CNY 4,120,892.82 for the quarter, after accounting for tax effects[5]. - The company experienced a foreign exchange loss of CNY -272,954.05 in Q1 2023, compared to a loss of CNY -48,275.32 in Q1 2022[20].